论文部分内容阅读
目的 观察自体淋巴因子活化的杀伤细胞 (LAK细胞 )回输治疗慢性乙型肝炎的远期疗效。方法 治疗组 (n =15 0例 )采用自体LAK细胞回输 ,对照组 (n =12 0例 )采用常规治疗。两组患者分别在治疗结束后及 1、2、3、5、7、10年内检查肝功能、HBVM、PCR HBV DNA、肝脏B超、X线食管钡餐透视 ,统计肝癌发生例数和病死例数。结果 治疗组各项实验室检查指标与对照组比较差异有显著意义 ;治疗组死亡 1例 ,对照组死亡 4 6例 ;治疗组无肝癌发生 ,对照组有 12例发生肝癌。结论 自体LAK细胞回输治疗慢性乙型肝炎有较好的远期疗效
Objective To observe the long-term efficacy of reinfusion of autologous lymphokine-activated killer cells (LAK cells) in the treatment of chronic hepatitis B patients. Methods The treatment group (n = 150) was transfused with autologous LAK cells and the control group (n = 120) received routine treatment. Two groups of patients were examined liver function, HBVM, PCR HBV DNA, liver B ultrasound, barium meal of X-ray esophagus after the treatment and 1,2,3,4,7,10 respectively . Results There were significant differences between the two groups in the index of laboratory examination and the control group. One case died in the treatment group and 46 cases died in the control group. There was no liver cancer in the treatment group and 12 cases in the control group. Conclusion Autologous LAK cell transfusion has good long-term efficacy in the treatment of chronic hepatitis B.